(19) |  |
| (11) | EP 4 219 552 A3 |
(12) | EUROPEAN PATENT APPLICATION |
(88) | Date of publication A3: | | 13.09.2023 Bulletin 2023/37 |
(43) | Date of publication A2: | | 02.08.2023 Bulletin 2023/31 |
(22) | Date of filing: 06.02.2014 |
| (51) | International Patent Classification (IPC): |
|
(84) | Designated Contracting States: | | AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
(30) | Priority: | 07.02.2013 AU 2013900389 14.02.2013 US 201361764756 P
|
(62) | Application number of the earlier application in accordance with Art. 76 EPC: | | 14749445.4 / 2953971 |
(71) | Applicant: CSL Ltd. | | Melbourne, VIC 3000 (AU) |
| (72) | Inventors: | | - EDWARDS, Kirsten Mae
Parkville, 3052 (AU) - HARDY, Matthew Philip
Parkville, 3052 (AU) - RAYZMAN, Veronika
Parkville, 3052 (AU) - WILSON, Michael
Parkville, 3052 (AU)
|
(74) | Representative: Carpmaels & Ransford LLP | | One Southampton Row London WC1B 5HA London WC1B 5HA (GB) |
|
| |
(54) | IL-11R BINDING PROTEINS AND USES THEREOF |
(57) The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11Rα) and uses thereof, e.g., in therapy.